AstraZeneca among 10 drugmakers to partner with Genomics England

Ten drugmakers have partnered with Genomics England to take advantage of developments that have come from the 100,000 Genomes Project.

Companies including AstraZeneca (LSE: AZN), GlaxoSmithKline (LSE: GSK) and AbbVie (NYSE: ABBV) have formed the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long trial involving a selection of whole-genome sequences in oncology and rare diseases.

Genomics England says the project "will transform treatment for patients with cancer and rare diseases, providing faster access to the right treatment and personalized care to tackle complex diseases.”